Charlotte Kirby Charlotte Kirby

Arecor Therapeutics posts solid interim results

Cambridge biopharma company Arecor Therapeutics saw its share price rise more than two per cent after posting a solid set of interim results to June 30 and predicting a transformative next six months for its diabetes franchise.

Read More
Charlotte Kirby Charlotte Kirby

UK’s FocalPoint raises $17M for its software-based approach to repairing the flaws of GPS

GPS in its many regional flavors has become a ubiquitous feature in phones, smart watches, cars and other connected devices, but for all the location-based features that it helps enable (mapping being the most obvious) it has a lot of shortcomings: it can be slow and inaccurate, it can contribute to faster battery drain and, as people are discovering, it can be manipulated or exploited in unintended and alarming ways.

Read More
Charlotte Kirby Charlotte Kirby

Stemnovate set for take-off after being grounded by Covid

It would be considered vulgar in some quarters to call it a rags to riches story, given the quality of the relevant company’s liver-on-chip technology but the financial bounceback of Stemnovate represents a remarkable upturn in fortunes nevertheless.

Read More
Charlotte Kirby Charlotte Kirby

Arecor goes from strength to strength

Upbeat Arecor Therapeutics, the Cambridge biopharma company, reveals it is continuing discussions with potential partners to expand its portfolio of revenue generating partnership deals.

Read More